Biocept Inc. began trading on the Nasdaq on Feb. 5, raising $19 million. It offered 1.9 million at $10 per share, but by Feb. 6 the stock dropped to $8.65.
Biocept’s IPO put the company’s market value at $48 million, according to Renaissance Capital.
The company makes blood tests that help oncologists choose the right treatment for their patients. It is trading under ticker symbol “BIOC.”
SDBJ Staff Report